<DOC>
	<DOC>NCT01875263</DOC>
	<brief_summary>Evaluate the efficacy of a sequential regimen of 14 days in patients with catheter-related bacteremia by S. aureus methicillin-susceptible, selected based on a pre-established clinical and microbiological criteria.</brief_summary>
	<brief_title>Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<criteria>Patients â‰¥ 18 years with a minimum weight of 40 kg. Microbiological Isolation of S. aureus susceptible to meticillin. Start antibiotic treatment with drugs active against S. aureus within 72 hours from the onset of clinical manifestations. Women of childbearing potential, negative pregnancy test negative serum or urine or statement is not pregnant. Prescription prior treatment must be independent and decoupled patient inclusion in the study, corresponding exclusively to clinical practice. Polymicrobial bacteremia. Neutropenic patients. Patients addicted to intravenous drugs. Patients with malignancies with expected survival less than 6 months. Severe allergy to betalactams or fluoroquinolones. Creatinine clearance &lt;20ml/min. Need for hemodialysis, peritoneal dialysis or plasmapheresis. Clinical signs of deep infection in the first five days of treatment (mucocutaneous lesions suggestive of IE, embolic events, suppurative thrombophlebitis. Predictors of bacteremia complicated: Positive blood cultures for 4896 hours of starting treatment antistaphylococcal Clinical Instability Signs of sepsis or persistent fever at day 4 of treatment Existence of valvular or vascular prosthetic joints, vascular catheter not removed within three days Heart disease predisposing to endocarditis. Patients presenting diagnosis concomitant infection by another organism. Pregnant or breastfeeding. Patients with epilepsy. Patients with a history of tendon disorders related to fluoroquinolone administration. Not have signed informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>catheter-related bacteremia, SAMS</keyword>
	<keyword>catheter related bacteremia</keyword>
	<keyword>susceptible</keyword>
	<keyword>aureus meticillin</keyword>
</DOC>